change in patient-reported outcomes (pros) and the relationship with clinical parameters in patients with Type 2 diabetes receiving once weekly dulaglutide or insulin glargine in the Assessment of Weekly Administration of Dulaglutide in Diabetes (award-2 and -4) studies : p149